Literature DB >> 2758101

Disposition kinetics of Saccharomyces boulardii in man and rat.

H Blehaut1, J Massot, G W Elmer, R H Levy.   

Abstract

Entities:  

Mesh：

Year:  1989        PMID： 2758101     DOI： 10.1002/bdd.2510100403

Source DB:  PubMed          Journal:  Biopharm Drug Dispos        ISSN： 0142-2782            Impact factor:   1.627


× No keyword cloud information.
  32 in total

Review 1.  Systematic review and meta-analysis of Saccharomyces boulardii in adult patients.

Authors:  Lynne V McFarland
Journal:  World J Gastroenterol       Date:  2010-05-14       Impact factor: 5.742

2.  Probiotics and Gastrointestinal Disease: Clinical Evidence and Basic Science.

Authors:  Elaine O Petrof
Journal:  Antiinflamm Antiallergy Agents Med Chem       Date:  2009-09-01

3.  Use of artificial digestive systems to investigate the biopharmaceutical factors influencing the survival of probiotic yeast during gastrointestinal transit in humans.

Authors:  Stéphanie Blanquet-Diot; Sylvain Denis; Sandrine Chalancon; Fehd Chaira; Jean-Michel Cardot; Monique Alric
Journal:  Pharm Res       Date:  2011-11-09       Impact factor: 4.200

Review 4.  Effects of Saccharomyces boulardii on intestinal mucosa.

Authors:  Jean-Paul Buts; Nadine De Keyser
Journal:  Dig Dis Sci       Date:  2006-07-13       Impact factor: 3.199

5.  Effects of Saccharomyces boulardii on fecal short-chain fatty acids and microflora in patients on long-term total enteral nutrition.

Authors:  Stephane-M Schneider; Fernand Girard-Pipau; Jerome Filippi; Xavier Hebuterne; Dominique Moyse; Gustavo-Calle Hinojosa; Anne Pompei; Patrick Rampal
Journal:  World J Gastroenterol       Date:  2005-10-21       Impact factor: 5.742

6.  Treatment of Recurrent Clostridium difficile Diarrhea.

Authors:  Elizabeth S Huebner; Christina M Surawicz
Journal:  Gastroenterol Hepatol (N Y)       Date:  2006-03

7.  Influence of antibiotics on the recovery and kinetics of Saccharomyces boulardii in rats.

Authors:  A V Boddy; G W Elmer; L V McFarland; R H Levy
Journal:  Pharm Res       Date:  1991-06       Impact factor: 4.200

8.  Recovery and elimination of the biotherapeutic agent, Saccharomyces boulardii, in healthy human volunteers.

Authors:  S M Klein; G W Elmer; L V McFarland; C M Surawicz; R H Levy
Journal:  Pharm Res       Date:  1993-11       Impact factor: 4.200

9.  Recombinant Saccharomyces cerevisiae expressing P450 in artificial digestive systems: a model for biodetoxication in the human digestive environment.

Authors:  S Blanquet; J P Meunier; M Minekus; S Marol-Bonnin; M Alric
Journal:  Appl Environ Microbiol       Date:  2003-05       Impact factor: 4.792

Review 10.  Saccharomyces boulardii in childhood.

Authors:  Yvan Vandenplas; Oscar Brunser; Hania Szajewska
Journal:  Eur J Pediatr       Date:  2008-12-19       Impact factor: 3.183
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.